Results 191 to 200 of about 94,212 (236)

Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection. [PDF]

Viruses
Barbu RE, Ignat MD, Bogdan Goroftei RE, Baltă AAȘ, Lutenco V, Bulza V, Stoian VI, Cambrea SC, Dumea E, Baroiu L.   +9 more
europepmc   +1 more source

Applications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review

Smart Molecules, EarlyView.
This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta, Susanta Paul, Swarupananda Mukherjee, Nilanjan Sarkar, Arvind Kumar, Amrita Chakraborty, Anannya Bose, Atanu Hazra, Mainak Chakraborty   +8 more
wiley   +1 more source

Current and Future Landscape of Hepatocellular Carcinoma Treatment. [PDF]

Oncol Res
Zerehpoosh S, Tanaka Y, Al-Busafi SA, Aghayeva G, Rouabhia S, Pan Q, Eslam M.   +6 more
europepmc   +1 more source

GLUT1 Deficiency Syndrome with Coexistent Movement Disorder and Anemia

Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan, Haya S AlFaris, Anika Menetrey, Sayoni Roy Chowdhury, Lindsey Vogt, Jolynn Dickson, Karen Owusu, Pradeep Krishnan, Suvasini Sharma, Liali Aljouda, Reena Pabari, Grace Yoon, Carolina Gorodetsky   +12 more
wiley   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Innate immune recognition and evasion strategies of hepatitis B virus: from DNA to RNA and viral proteins. [PDF]

Front Immunol
Chen Z, Hu R, Ye H, Chen Q, Liu Y, Zhang X, Chen Y, Wu Y, Jin C.   +8 more
europepmc   +1 more source

Sugammadex vs. neostigmine and the risk of postoperative pulmonary complications after upper gastrointestinal endoscopic procedures: a propensity score matched analysis of 15,730 patients

Anaesthesia, EarlyView.
Summary Introduction Postoperative pulmonary complications after upper gastrointestinal endoscopic procedures under general anaesthesia are clinically important and may be exacerbated by residual neuromuscular block. We evaluated whether antagonism of neuromuscular block with sugammadex rather than neostigmine is associated with improved respiratory ...
Yung‐Fong Tsai, Kuo‐Chuan Hung, Chih‐Yi Hsu, Huan‐Tang Lin, Yi‐Chen Lai, Shao‐Chun Wu   +5 more
wiley   +1 more source

Crystal structure of the CD33/Fab-10C8 complex elucidates the mechanism of antibody antagonism in HBV-induced immunosuppression. [PDF]

J Biomed Sci
Yeh YH, Lin MG, Sung PS, Hsieh SL, Hsiao CD.   +4 more
europepmc   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

Nanoparticle approaches for hepatitis therapy and clinical translation. [PDF]

Discov Nano
Mohamed NA, Atifi F, Ourradi Z, Crovella S, Derbala M, Yassine HM, Agbani EO, Merhi Y, Zaid Y, Abou-Saleh H.   +9 more
europepmc   +1 more source